Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.arGEN-X has signed an agreement with Eli Lilly (Lilly) for the discovery and development of new therapeutic antibody products against targets submitted by Lilly.
Subscribe to our email newsletter
As per the terms of the agreement, arGEN-X expects to develop new human monoclonal antibody (mAb) candidates that act on various functional sites on Lilly targets.
However, Lilly will select the most efficient candidate so as to progress that particular product into preclinical and clinical development including its commercialization.
The tie up allows arGEN-X to get milestone payments, license fees and research funding from Lilly.
Lilly has exclusive rights to develop and commercialize mAb-based products discovered in the collaboration.
Other financial and deal terms were not disclosed.
arGEN-X CEO Tim Van Hauwermeiren said that the signing of this alliance with Lilly is a major highlight for arGEN-X and is evidence of the potential of the SIMPLE Antibody platform.